Financial Statements
Supernus Pharmaceuticals, Inc. (SUPN)
$35.45
+0.86 (+2.49%)
Retained Earning Schedule
| Year | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Retained Earnings (Previous Year) | 380 | 326 | 200 | 86 | - |
| Net Income | 61 | 53 | 127 | 113 | 111 |
| Stock Dividends | 41 | - | - | - | -25 |
| Dividend Paid | - | - | - | - | - |
| Retained Earnings | 481 | 380 | 326 | 200 | 86 |
PPE Schedule
| Year | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Gross PPE | 17 | 38 | 38 | 4 | - |
| Annual Depreciation | -1 | -19 | 3 | 37 | 5 |
| Capital Expenditure | -0 | -2 | -3 | -3 | -1 |
| Net PPE | 15 | 17 | 38 | 38 | 4 |
Intangible and Goodwill Schedule
| Year | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Intangible and Goodwill (Previous Year) | - | - | - | 78 | 118 |
| New Purchases | -492 | -410 | -96 | -312 | -407 |
| Intangible and Goodwill | - | - | 78 | 118 | 117 |
Supernus Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Supernus Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.